Resmed holds a large investment in Apnimed, developer of AD-109. There, Chief Medical Officer, Carlos Nunez, sits on Apnimed's scientific advisory board.AD109 is now entering phase 3 trials.
Are we worried about this other product ? There trials have been conducted over a Large scale.
Add to My Watchlist
What is My Watchlist?